Nurix Therapeutics Inc.
NASDAQ · NRIX·San Francisco, CA·Small-cap·Phase 2
Pioneering targeted protein degradation medicines for cancer and autoimmune diseases. Lead program bexobrutideg (NX-5948) is a brain-penetrant BTK degrader in pivotal Phase 2 for relapsed/refractory CLL, with FDA Fast Track and EMA PRIME designations.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Nurix Therapeutics Investor Presentation April 2026 | Corporate overview | April 1, 2026 | 77 |